Impact of Trimethoprim‐Sulfamethoxazole Prophylaxis on Falciparum Malaria Infection and Disease
Author(s) -
Mahamadou A. Théra,
Paul S. Sehdev,
Drissa Coulibaly,
Karim Traoré,
Mamane Nassirou Garba,
Yacouba Cissoko,
Abdoulaye K. Koné,
Ando B. Guindo,
Alassane Dicko,
Abdoul Habib Béavogui,
Abdoulaye Djimdé,
Kirsten E. Lyke,
Dapa A. Diallo,
Ogobara K. Doumbo,
Christopher V. Plowe
Publication year - 2005
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/498249
Subject(s) - sulfamethoxazole , sulfadoxine , malaria , trimethoprim , medicine , pyrimethamine , malaria prophylaxis , plasmodium falciparum , drug resistance , human immunodeficiency virus (hiv) , immunology , virology , antibiotics , microbiology and biotechnology , biology
Trimethoprim-sulfamethoxazole (TS) prophylaxis is recommended for persons living with human immunodeficiency virus infection and acquired immunodeficiency syndrome in Africa. TS and the antimalarial combination sulfadoxine-pyrimethamine (SP) share mechanisms of action and resistance patterns, and concerns about the impact of TS resistance on SP efficacy have contributed to reluctance to implement TS prophylaxis in Africa.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom